

ESTTA Tracking number: **ESTTA363319**

Filing date: **08/16/2010**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD

## Petition for Cancellation

Notice is hereby given that the following party requests to cancel indicated registration.

### Petitioner Information

Name	Thomas Skold		
Entity	Individual	Citizenship	SWEDEN
Address	Bj�rn� G�rd, S-71 41 Norrt�lje, S-71 41 SWEDEN		

Attorney information	Arthur E. Jackson Moser IP Law Group 1030 Broad Street, Suite 203 Shrewsbury, NJ 07702 UNITED STATES docketing@moseriplaw.com Phone:(732) 935-7100
----------------------	---

### Registrations Subject to Cancellation

Registration No	2985751	Registration date	08/16/2005
Registrant	GALDERMA LABORATORIES, INC. 14501 NORTH FREEWAY FORTH WORTH, TX 76177 UNITED STATES		

### Goods/Services Subject to Cancellation

Class 005. First Use: 2005/05/27 First Use In Commerce: 2005/05/27 All goods and services in the class are cancelled, namely: THERAPEUTIC SKIN CARE PREPARATIONS AND TREATMENT FOR SKIN DISORDERS
--

### Grounds for Cancellation

Other	Mark is no longer owned by Registrant		
Registration No	3394514	Registration date	03/11/2008
Registrant	GALDERMA LABORATORIES, INC. 14501 NORTH FREEWAY FORTH WORTH, TX 76177 UNITED STATES		

### Goods/Services Subject to Cancellation

Class 003. First Use: 2007/06/21 First Use In Commerce: 2007/06/21 All goods and services in the class are cancelled, namely: Non-medicated skin care preparations
---

### Grounds for Cancellation

Other	Mark is no longer owned by Registrant		
-------	---------------------------------------	--	--

Related Proceedings	None
---------------------	------

Attachments	SKDPetitionforCancellation20100816.pdf ( 9 pages )(103267 bytes ) Exhibits1_6_8.pdf ( 7 pages )(325661 bytes )
-------------	---

### **Certificate of Service**

The undersigned hereby certifies that a copy of this paper has been served upon all parties, at their address record by First Class Mail on this date.

Signature	/Arthur E Jackson/
Name	Arthur E. Jackson
Date	08/16/2010

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD

In the Matter of Registration Nos. 2985751; and 3394514

Dated: August 16, 2005 & March 11, 2008, Respectively

Thomas Sköld,	)	
Petitioner,	)	
	)	
v.	)	
	)	Cancellation No. _____
Galderma Laboratories, Inc.,	)	
Registrant	)	
	)	

BOX TTAB/FEE  
Commissioner for Trademarks  
2900 Crystal Drive  
Arlington, VA 22202-3513

**PETITION FOR CANCELLATION**

Thomas Sköld an individual who is a citizen of Sweden, and resident at Björnö Gård, S-71 41, Norrtälje, Sweden, believes that he will be damaged by Registration No. 2985751 as it relates to goods in Class 5, namely therapeutic skin care preparations and treatment for skin disorders , and by Registration No. 3394514 as it relates to goods in Class 3, namely non-medicated skin care preparations, and hereby petitions to cancel the registration of the mark RESTORADERM for these goods.

As grounds therefor, it is alleged that:

1. Petitioner has adopted and continuously used the trademark RESTORADERM, since at least as early as December, 2001 to the present, in connection with presentations and promotions of a

technology utilizing phospholipid and/or ceramide, cholesterol and fatty acid for dermally and transdermally delivering bioactive substances ("Technology").

2. Collagenex Pharmaceuticals Inc. ("Collagenex") is the predecessor in interest to the current record owner of said '751 and '514 registrations, Registrant. In 2008, Registrant acquired all outstanding stock of Collagenex. See <http://www.prnewswire.com/news-releases/galderma-reaches-agreement-to-acquire-collagenex-pharmaceuticals-57139647.html>, attached as Exhibit 1.

3. The change of ownership from Collagenex to Registrant was recorded at Reel/Frame: 4109/0411, on 12/08/2009.

4. Under either contract theory supported below, Registrant no longer owns the trademark *RESTORADERM*. So Petitioner, the true owner, seeks cancellation of Registrant's registrations.

#### First Contract Theory

5. In late 2001, Petitioner presented to Collagenex the Technology, which he labeled the "Restoraderm Technology." Prior to such presentation, on information and belief, Collagenex did not use the trademark *RESTORADERM*. Thereafter, Collagenex filed the application leading to the '751 registration in late February 2002, and collaborated with Sköld on the filing of a first provisional patent application on the Technology in March, 2002.

6. Petitioner licensed the trademark *RESTORADERM* and the associated Technology to Collagenex Pharmaceuticals Inc. ("Collagenex"), the predecessor in interest to the current owner of said '751 and '514 registrations, Galderma Laboratories Inc. ("Galderma"), in an Agreement effective February 11, 2002 (the "2002 Agreement", to be provided as Exhibit 2, subject to a protective order).

7. Petitioner cannot locate a copy of Exhibit A to the 2002 Agreement. On information and belief, either such exhibit was not part of the agreement, or it listed the RESTORADERM trademark. Based on Section 4.2 of the 2002 Agreement, the RESTORADERM trademark was clearly part of the subject matter of the agreement.

8. Petitioner acquired modified rights in the Technology, labeled "Restoraderm Technology," to Collagenex Pharmaceuticals Inc. in an agreement effective August 19, 2004 (the "2004 Agreement", to be provided as Exhibit 3, subject to a protective order). The 2004 Agreement superseded the 2002 Agreement as to the Restoraderm Technology.

9. Whether the 2004 Agreement superseded the 2002 Agreement as to the RESTORADERM trademark depends on whether one interprets Section 2.1(d) of the 2004 Agreement as covering the trademark. If yes, then the analysis under the first theory is foreclosed, but the analysis under the second theory is strengthened; if no, then the 2004 Agreement is silent as to the trademark, which as outlined below will lead to the conclusion that the trademark element of the 2002 Agreement is not superseded. This analysis under the first contract theory presumes that the answer is no. Hence, per the analysis below, the trademark RESTORADERM remained licensed under the 2002 Agreement, and is subject to the "terms and conditions" of that agreement. The most basic condition and purpose of the 2002 Agreement was that Collagenex participate in and control the development of the technology. See, second whereas recital of the 2002 Agreement, and the Collagenex participation outlined in Sections 3.1 and 7 thereof.

10. Since specific provisions usually take precedence over general language<sup>1</sup>, Section 9.12 of the 2004 Agreement governs what portions of the 2002 Agreement were superseded. Per this Section 9.12, only prior agreements *respecting the subject matter of the 2004 Agreement* are

---

<sup>1</sup> Williston on Contracts § 32.10 (4th ed. 2007)

superseded. This specific language governs over the general language of the introductory whereas recitals drafted when trademarks were part of the initial discussions on forming 2004 Agreement. Moreover, specific terms in the body of a contract control over recitals contained in a "whereas" clause. See, Neal D. Ivey Co. v. Franklin Associates, 87 A.2d 236, 239 (Pa. 1952). Since the 2004 Agreement is not respecting the trademark, it does not supersede the trademark agreement, i.e., this aspect of the 2004 Agreement.

11. Collagenex in a letter dated February 12, 2008 ("February 2008 Letter", to be provided as Exhibit 4, subject to a protective order), clearly acknowledged that it had a duty to Sköld with respect to the trademark

12. On information and belief, Registrant is the successor in interest in the registrations and in the 2002 and 2004 Agreements.

13. In a letter dated November 27, 2009 ("November 2010 Letter"), Registrant terminated the 2004 Agreement (to be provided as Exhibit 5, subject to a protective order). Such termination must necessarily also terminate the surviving portion of the 2002 Agreement licensing the trademark. The very purpose of the 2002 Agreement is negated by the termination of the 2004 Agreement.

#### Second Contract Theory

14. If the fact finder deems the first theory incorrect, Petitioner submits that it would be because the fact finder deems the first "whereas" recital in the 2004 Agreement to terminate the 2002 Agreement, or deems the 2004 Agreement to cover trademarks. If so, Registrant nonetheless submits that the trademark RESTORADERM is owned by him due to (a) the trademark being part of that recited in Section 2.1 of the 2004 Agreement or (b) a fatal ambiguity in the 2004

Agreement as to the trademark subject matter, which in turn implicates parole evidence which clearly indicates that trademark RESTORADERM was a subject of the 2004 Agreement.

15. Under Pennsylvania law, a contract will be found to be ambiguous if, and only if, it is reasonably or fairly susceptible to different constructions, is capable of being understood in more senses than one, is obscure in meaning through indefiniteness of expression, or has a double meaning. Erie Insurance Company/Erie Insurance Exchange v. Flood, 649 A.2d 736, 738 (Pa. Cmwlth. 1994).

16. The 2004 Agreement identifies the Intellectual Property by the trademark RESTORADERM, using the phrase "Restoraderm Intellectual Property," yet does not recite that the trademark is part of the batch of rights defined as Restoraderm Intellectual Property.

17. The items subject to the 2004 Agreement include that identified in Section 2.1(d), which by its plain meaning must include the trademark RESTORADERM.

18. Since items subject to the 2004 Agreement included the trademark RESTORADERM, then pursuant to Section 8.5(b)(iii), the trademark must be transferred to Sköld as a result of the November 2009 Letter (Exhibit 5). Consistent with Section 8.5(b)(iii) the patent estate in the Technology has been transferred to Sköld (see assignment, attached as Exhibit 6).

19. Parole evidence confirming that the trademark RESTORADERM was intended to be included in the items subject to the 2004 Agreement includes the discussion of trademark diligence in the February 2008 Letter (Exhibit 4). Further evidence is provided by an early draft of the 2004 Agreement that included an Exhibit B that was an unconditional trademark assignment (to be provided as Exhibit 7, subject to a protective order).

### Damage and Relief

20. Since the Board cannot order the transfer of the trademarks, Petitioner seeks to remove any stain of Registrant's apparent ownership of RESTORADERM on Petitioner's applications for BASED ON RESTORADERM LIPOGRID TECHNOLOGY (Serial No. 85037342) and RESTORADERM LIPIDGRID (Serial No. 85037362).

21. If the Registrant is permitted to retain the registrations sought to be cancelled, and thereby, the *prima facie* exclusive right to use in commerce the mark *RESTORADERM* on the recited subject matter, its use of the mark will continue to confuse dermatologists familiar with the Technology.

22. On information and belief, Registrant intends to market in the United States the same Cetaphil RESTORADERM that it markets in Canada, and which contains water, glycerin, caprylic/capric triglyceride, sunflower seed oil, pentylene glycol, shea butter, sorbitol, cyclopentasiloxane, cetearyl alcohol, behenyl alcohol, glyceryl stearate, tocopheryl acetate, hydroxypalmitoyl sphinganine, cetyl alcohol, arginine, disodium ethylene dicocamide PEG-15 disulfate, glyceryl stearate citrate, niacinamide, sodium PCA, ceteareth-20, sodium polyacrylate, caprylyl glycol, allantoin, citric acid, panthenol, dimethiconol, disodium EDTA, and sodium hyaluronate. See <http://rosacea-support.org/cetaphil-restoraderm-for-extra-dry-skin-and-eczema.html>, attached as Exhibit 8. Such a product does not reflect the Technology since it contains no phospholipid and/or ceramide, cholesterol and fatty acid as a delivery system.

23. On information and belief, two dermatologists have called, and one has emailed Petitioner to ask if the Cetaphil RESTORADERM product is according to the Technology, clearly indicating confusion.



24. Physician purchasers are likely to consider the goods of Registrant sold under the mark RESTORADERM as emanating from Petitioner, and purchase such goods as those of the Petitioner, resulting in loss of development opportunities to Petitioner.

25. Concurrent use of the mark by the Registrant and Petitioner may result in irreparable damage to Petitioner's reputation and goodwill, if the goods sold by the Registrant are inferior, since purchasers are likely to attribute the source of the Registrant's goods to the Petitioner.

26. If the Registrant is permitted to retain the registration sought to be cancelled, a cloud will be placed on Petitioner's title in and to its trademark, *RESTORADERM*, and on its right to enjoy the free and exclusive use thereof in connection with the sale of its goods, all to the great injury of Petitioner.

#### Additional

27. Exhibits 2, 3, 4, 5 and 7 are withheld from this submission to the Board pending resolution of any potential issues of confidentiality. These exhibits have been served upon the Registrant in a separate envelop labeled "CONFIDENTIAL EXHIBITS."

**WHEREFORE**, Petitioner deems that it is or will be damaged by Registration Nos. 2985751 and 3394514, and petitions for cancellation thereof as it relates to goods in Classes 5 and 3, respectively.

Respectfully submitted,

Date: August 16, 2010

By: /Arthur E Jackson/

Arthur E. Jackson, Ph.D., Esq.  
New Jersey Bar No. 00288-1995  
ajackson@moseriplaw.com  
MOSER IP LAW GROUP  
1030 Broad Street, Suite 203  
Shrewsbury, NJ 07702  
(732) 935-7100  
(732) 935-7122  
Attorney for Petitioner

**CERTIFICATE OF SERVICE**

I hereby certify that a copy of the foregoing PETITION FOR CANCELLATION, together with all Exhibits 1-8, and a proposed consent agreement on Provisions for Protecting Confidentiality of Information Revealed During Board Proceeding was sent first class mail, postage pre-paid on this 16 day of August, 2010 to:

Attn: Quintin Cassady  
Vice President and General Counsel  
GALDERMA LABORATORIES, INC.  
14501 NORTH FREEWAY  
FORTH WORTH, TX 76177

I hereby certify that a copy of the foregoing PETITION FOR CANCELLATION, together with all Exhibits 1, 6 and 8, and a proposed consent agreement on Provisions for Protecting Confidentiality of Information Revealed During Board Proceeding was sent first class mail, postage pre-paid on this 16 day of August, 2010 to:

Attn: G. Mathew Lombard  
Lombard & Geliebter LLP  
10 FL  
230 PARK AVE  
NEW YORK NY 10169

**Exhibit 1**  
(Press Release)

Sköld v. Galderma

Cancellation No. \_\_\_\_

Re Registration Nos. 2985751 and 3394514

See more news releases in: Health Care & Hospitals, Medical Pharmaceuticals, Acquisitions, Mergers and Takeovers



## Galderma Reaches Agreement to Acquire CollaGenex Pharmaceuticals

Products and Pipeline to Enhance Galderma's Position in Dermatology

LAUSANNE, Switzerland and NEWTOWN, Pa., Feb. 26 /PRNewswire/ -- Galderma Pharma S.A., a global specialty pharmaceutical company focused on dermatology, and CollaGenex Pharmaceuticals, Inc. (Nasdaq: CGPI) today announced a definitive agreement pursuant to which Galderma's U.S. holding company, Galderma Laboratories, Inc., will acquire all of the outstanding shares of CollaGenex at a price of \$16.60 per share in cash, representing approximately \$420 million for the equity of CollaGenex. The transaction was unanimously approved by the boards of directors of Galderma and CollaGenex.

"Galderma is committed to provide innovative medical solutions to dermatology patients and physicians across the globe," said Humberto C. Antunes, Chief Executive Officer of Galderma. "CollaGenex' innovative products complement and enhance Galderma's portfolio. We admire the accomplishments of CollaGenex' employees and believe our combined organizations will be even better positioned to serve patient's needs. This transaction should be neutral to Galderma's net income in 2008 and accretive as of 2009."

CollaGenex launched Oracea(R), the first FDA-approved systemic product indicated for the treatment of rosacea, in July 2006. CollaGenex is also developing Col-118, an innovative product for the treatment of the erythema associated with rosacea. If approved, Col-118 would be the first effective treatment for erythema. In addition, CollaGenex is developing a product with the potential to provide added benefits for the treatment of psoriasis.

"The immediate implication for the U.S. market is very positive," said Albert Draaijer, President of Galderma's U.S. operations. "CollaGenex' oral rosacea therapy will be an important complement to Galderma's topical products, providing improved options that treat a condition affecting more than 14 million Americans."

Colin W. Stewart, President and Chief Executive Officer of CollaGenex, said, "Galderma was the first pharmaceutical company to develop a topical product indicated for the treatment of rosacea. Oracea, combined with the successful development of Col-118, will enable Galderma to offer physicians and patients a full suite of complementary pharmaceutical products to treat rosacea."

Mr. Stewart continued, "We are very proud of the accomplishments of the entire CollaGenex team over the past several years as we made our successful transition into dermatology and created the largest oral drug indicated for the treatment of rosacea in the U.S. We are pleased that Galderma recognizes the value that we have created, and we believe that this transaction provides compelling value for our shareholders."

The merger agreement provides for Galderma to acquire CollaGenex in a two-step transaction. The first step will consist of a cash tender offer for all outstanding shares of CollaGenex common stock at a price of \$16.60 per share in cash. In the second step, the tender offer will be followed by a merger in which the holders of the outstanding shares of CollaGenex common stock not tendered in the offer will receive the same per share price paid in the tender offer, in cash. Upon completion of the merger, CollaGenex will become a wholly owned subsidiary of Galderma.

The tender offer will be conditioned upon the tender of a majority of the outstanding shares of CollaGenex common stock and will also be subject to regulatory clearances and other customary closing conditions. Certain holders of CollaGenex' Series D-1 Preferred Stock, representing 95% of the outstanding Series D-1 Preferred Stock and approximately 9% of CollaGenex' shares on a fully diluted basis, have entered into an agreement to sell their shares of preferred stock to Galderma immediately following, but subject to, the closing of the tender offer at the price paid in the offer with respect to the underlying CollaGenex common stock. The transaction is expected to close before the end of the second quarter 2008.

Credit Suisse acted as financial adviser to Galderma, and Debevoise & Plimpton LLP as legal counsel. Cowen and Company acted as financial adviser to CollaGenex, and Milbank Tweed Hadley & McCloy LLP served as CollaGenex' legal counsel.

About Galderma

RSS Feeds

Print

Email

Share it

Blog it

Blog Search

### Other News Releases in Health Care & Hospitals

Massachusetts Memory Walk® Raises Awareness and Dollars to Fight Alzheimer's

Aspen University Announces Launch of \$100 per Credit Hour Online Degree Programs in Psychology of Addiction and Counseling

U.S. Soccer Hero Landon Donovan, Who Wore Number TEN in the World Cup, and The Leukemia & Lymphoma Society Launch a TEN Day Mobile Giving Campaign

### Other News Releases in Acquisitions, Mergers and Takeovers

Sandata Technologies Acquires Medical Management Technology Group's Home Healthcare Customers

UBM Aviation Acquires The Route Development Group

Red Ventures Announces Growth Capital Investment by General Atlantic

### Journalists and Bloggers

Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.

View and download archived video content distributed by MultiVu on The Digital Center.

**Exhibit 6**  
(Patent Assignment)

Sköld v. Galderma  
Cancellation No. \_\_\_\_  
Re Registration Nos. 2985751 and 3394514

132,205

# ASSIGNMENT OF PATENTS

WHEREAS, Galderma Laboratories, Inc., ("Assignor"), a corporation, having its main office and place of business at 11 North Freeway, Fort Worth, Texas 76177 U.S.A. is the owner of the entire right, title and interest in and to the following United States patent application(s) and all corresponding non-US patent applications including those listed below:

Country	Application Number	Filing Date	Title
US	10/388,371	03/13/2003	Water-Based Topical Delivery System
US	10/957,320	09/30/2004	Water-Based Delivery Systems
US	12/082,406	04/09/2008	Water-Based Delivery Systems
US	12/290,455	10/30/2008	Water-Based Delivery Systems
US	60/365,059	03/13/2002	Water-Based Topical Delivery System
US-PCT	WO2003US07752	03/13/2003	Water-Based Delivery Systems
US-PCT	WO2005US35531	09/30/2005	Water-Based Delivery Systems

Country	Application Number	Country	Application Number
AU-Australia	2003233396	JP-Japan	2003-575915
AU-Australia	2007211879	KR-Korea (South)	2004-7014070
CA-Canada	2,476,859	NZ-New Zealand	534377
EP-European Pat. Org	03728242.3		

AND WHEREAS, Thomas Sköld ("Assignee"), an individual residing at Björns Gård, S-71 41, Norrtälje, Sweden, is desirous of acquiring said right, title and interest;

NOW THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, Assignor does hereby assign and transfer to Assignee and its successors and assigns, the entire right, title and interest in and to the above-identified patents applications, including all reissues, divisions, continuations, continuation-in-part, and extensions and foreign counterparts thereof, to be held and enjoyed by Assignee as fully and entirely as it would have been held and enjoyed by Assignor if this assignment had not been made, including all claims, demands and right recovery that Assignor has or may have in profits and damages for past and future infringements, if any, and all rights to compromise, sue for, and collect such profits and damages.

In the event of any inconsistency between this Assignment and Article 8 of the August 19, 2004 Asset Purchase and Product Development Agreement between Thomas Sköld and CollaGenex Pharmaceuticals, Inc. (to which company Galderma Laboratories, Inc. is the successor in interest), Article 8 shall be controlling.

This Agreement may be executed in any number of counterparts and each such counterpart shall be deemed to be an original.

For Galderma Laboratories, Inc.

For Thomas Sköld

Name: Quintin Cassady  
Title: Vice President


Name: Thomas Sköld

Dated: February 22, 2010

STATE OF TEXAS

COUNTY OF DENTON

On this 22nd day of February, 2010 before me appeared Quintin Cassady, the person who signed this instrument and acknowledged that he signed it as a free act on behalf of Galderma Laboratories, Inc.



Nora Anderson  
Notary Public

**Exhibit 8**  
(Rosacea Support Web Page)

Sköld v. Galderma  
Cancellation No. \_\_\_\_  
Re Registration Nos. 2985751 and 3394514



- [laser therapy](#) (32)
- [LED Therapy](#) (18)
- [macrolides](#) (14)
- [makeup](#) (13)
- [melanotan](#) (14)
- [metrogel](#) (23)
- [moisturizers](#) (24)
- [natural treatments](#) (47)
- [neutrogena](#) (1)
- [ocular rosacea](#) (39)
- [oracea](#) (27)
- [oxymetazoline](#) (5)
- [papules & pustules](#) (6)
- [patents](#) (19)
- [PDT](#) (8)
- [pulse dye laser](#) (8)
- [pyratine](#) (6)
- [red face](#) (24)
- [research](#) (67)
- [research foundation](#) (39)
- [reviews](#) (3)
- [rhinophyma](#) (12)
- [rosacea cause](#) (21)
- [sansrosa](#) (20)
- [scenese](#) (1)
- [seborrheic dermatitis](#) (18)
- [shaving](#) (2)
- [site admin](#) (2)
- [skin care](#) (9)
- [steroids](#) (5)
- [sunscreens](#) (14)
- [supplements](#) (4)
- [swelling](#) (8)
- [telangectasia](#) (6)
- [tetracyclines](#) (24)
- [To Be Filed](#) (6)
- [topicals](#) (51)
- [user reviews](#) (17)
- [VEGF](#) (6)

← [Research Briefs: IPL, Laser and Stress](#)

[Green Tea helps Red Light Therapy](#) →

## Cetaphil RestoraDERM for extra dry skin and Eczema

May 26th, 2010, by David Pascoe | [cleansers](#), [eczema](#), [galderma](#), [moisturizers](#)



Already available in Canada, Cetaphil will introduce a new line of products for dry sensitive skin in August in the US. The line is called RestoraDERM and is targeted at Eczema sufferers who struggle to maintain the natural moisture balance of their skin. For

For those rosacea sufferers who also have eczema or also struggle with moisturizing extra dry or itchy skin, this range may be worth a try.

I suspect that the moisturizer may initial seem thick compared to other moisturizers familiar to rosacea sufferers. Please leave a comment below if you do try them. What are they like ? Do they help you battle with any of you rosacea symptoms ?

The Canadian web site for RestoraDERM tells us that the soap-free liquid cleanser is said to encapsulate high levels of moisturizing oils to cleanse and hydrate dry skin, whilst the lotion is said to contain patented ceramide technology to replenish the skin's natural oils to help the skin to retain its natural moisture.



We are also told that both products are 'clinically proven to be suitable for total-body use—including the face' and are 'ideal for the entire family' and that the products have been demonstrated to relieve dryness and itching.

When Galderma acquired Collagenex in 2008, Collagenex listed a technology known as Restoraderm (along with Oracea and Sansrosa) as one of the assets acquired. Restoraderm at that time was described as a "proprietary, foam-based, topical drug delivery technology". It isn't clear to me whether this product is related to this technology or is something else entirely.

## Ingredients

Thanks to sans002 for the list of ingredients for this new range.

### Cetaphil RESTORADERM Eczema Moisturizing Wash Ingredients

water, shea butter, sodium trideceth sulfate, glycerin, sunflower seed oil, sodium chloride, sodium laurampoacetate, cocamide MEA, citric acid, niacinamide, sodium PCA, tocopheryl acetate, 1,2-Hexanediol and caprylyl glycol, disodium EDTA. guar hydroxypropyltrimonium chloride, allantoin, potassium sorbate, arginine, methylisothiazolinone

### Cetaphil RESTORADERM Eczema Moisturizing Lotion Ingredients

water, glycerin, caprylic/capric triglyceride, sunflower seed oil, pentylene glycol, shea butter, sorbitol, cyclopentasiloxane, cetearyl alcohol, behenyl alcohol, glyceryl stearate, tocopheryl acetate, hydroxypalmitoyl sphinganine, cetyl alcohol, arginine, disodium ethylene dicocamide PEG-15 disulfate, glyceryl stearate citrate, niacinamide, sodium PCA, cetareth-20, sodium polyacrylate, caprylyl glycol, allantoin, citric acid, panthenol, dimethiconol, disodium EDTA, sodium hyaluronate

## Related Articles

- Galderma CA: [RestoraDERM, Better Together](#)
- [Cetaphil moisturizing cream helps rosacea dry skin](#)
- [Cetaphil gentle skin cleanser well tolerated](#)
- [Cetaphil adds UVA/UVB Defense SPF 50](#)
- [Cetaphil spending a million pounds this spring](#)